Implementation of Meningococcal Vaccine Requirements

Guidance for Institutions of Higher Education

**Purpose**
This document will assist institutions of higher education with implementation of new meningococcal vaccine requirements. This guidance is effective immediately and will remain in effect until the New Jersey Department of Health (NJDOH) adopts rules and regulations pursuant to the “Administrative Procedure Act,” P.L.1968, c.410 (C.52:14B-1 et seq.).

**Background**
On January 13, 2020, P.L. 2019, c332 was signed into law. This new law amends P.L.2003, c.284 (N.J.S.A.18A:62-15.1) and shall take effect on June 15, 2020. In accordance with this law:

- A new student enrolling in a public or private institution of higher education shall have received immunization for meningococcal disease as recommended by the Advisory Committee on Immunization Practices (ACIP) as a condition of attendance. Students must present evidence of the vaccination(s) required.
- Each public and private institution of higher education in this State shall offer the required meningococcal vaccines through the institution’s student health services program or through a contracted agreement with a community health provider.

**Requirements for Institutions of Higher Education**
Public and private institutions of higher education must develop policies and procedures to ensure that all newly enrolling students are vaccinated for meningococcal disease in accordance with ACIP recommendations. A summary of recommendations is provided for your convenience; however, please review the complete ACIP guidance at: [www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html](http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html).

**Meningococcal vaccines**
Institutions of higher education must ensure that newly enrolled students receive meningococcal vaccines that are routinely recommended by the ACIP. There are 2 types of meningococcal vaccines available in the United States that are routinely recommended for certain persons:

**Meningococcal conjugate (MenACWY) vaccines (Menactra® and Menveo®)**
The ACIP routinely recommends vaccination for the following:

- **Children and adolescents through age 18**
  - All persons aged 11 – 12 years; booster dose at 16 years
  - All persons 16 – 18 years of age who have no history of prior vaccination are recommended to receive 1 dose
- **Adults 19 years of age and older**
  - First-year college students who live in residential housing (if not previously vaccinated at age 16 or older)
  - Persons with anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement deficiency, complement inhibitor use
  - Travel in countries with hyperendemic or epidemic meningococcal disease
Microbiologists routinely exposed to *Neisseria meningitidis*

- Persons who are at risk during an outbreak caused by vaccine serogroup

### Meningococcal B (MenB) vaccines (Bexsero® and Trumenba®)

The ACIP routinely recommends vaccination with the following:

- Persons 10 years of age and older
  - Persons with anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement deficiency, complement inhibitor use
  - Persons who are at risk during an outbreak caused by serogroup B
  - Microbiologists routinely exposed to *Neisseria meningitidis*

### Education on benefits of MenB vaccine

Institutions of higher education must ensure that newly enrolled students aged 16 through 23 years of age who are not routinely recommended to receive MenB vaccine (as noted above) receive education on the risks and benefits of MenB vaccine and that the vaccine be made available for students who choose to be vaccinated. ACIP recommends that a MenB series may be administered to people 16 through 23 years of age with a preferred age of vaccination of 16 through 18 years. This recommendation allows for shared clinical decision-making between the provider and the student based on the risk and benefit for the individual patients.

### Resources

The following resources are available to assist institutions of higher education with implementation of this new law. All of these materials are available on the NJDOH website at: https://nj.gov/health/cd/topics/meningo.shtml.

#### Meningococcal Disease Informational Flyer for College Students

This flyer provides students with an overview of meningococcal disease including how the disease is spread, symptoms, and vaccination recommendations. The student informational flyer may be disseminated or publicly posted to satisfy the education requirement (N.J.A.C. 8:57-6.10).

#### Meningococcal Vaccine Questionnaire for College Students

The document includes a checklist by age and increased risk for a student to self-assess which meningococcal vaccines they may be required to receive. This may serve as a template that can be adapted for sharing with students to help them determine if they are currently meeting the meningococcal vaccination requirements.

#### Algorithms for Meningococcal Immunization of College Students 16 Years and Older

These two documents may be used when determining which vaccines are recommended based on the ACIP recommendations for immunization. The algorithms provide specific dosing guidance based on age, and increased risk status. Two algorithms have been developed: one for MenACWY vaccination, and one for MenB vaccination.

#### Meningococcal Vaccination Guidance for Healthcare Providers

These two documents contain a current listing of the ACIP meningococcal vaccination recommendations for MenACWY and MenB vaccines. Recommendations are presented by age and risk factor.
Additional Information

- New Jersey Department of Health (NJDOH), Vaccine Preventable Disease Program
  https://nj.gov/health/cd/vpdp.shtml
- Meningococcal Disease, NJDOH
  https://nj.gov/health/cd/topics/meningo.shtml
- Meningococcal Disease, Centers for Disease Control and Prevention (CDC)
  https://www.cdc.gov/meningococcal/index.html
- Immunization Schedules, CDC
  https://www.cdc.gov/vaccines/schedules/index.html
- Meningococcal ACWY Vaccine Information Statement (VIS)
  https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html
- Meningococcal B Vaccine Information Statement (VIS)
  https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html

For further information, please contact the Vaccine Preventable Disease Program at 609-826-4861.
Table of Contents

Chapter 332 Pamphlet Law

MenACWY Algorithm

MenB Algorithm

MenACWY Clinician Guidance

MenB Clinician Guidance

Student Informational Flyer

Meningococcal Vaccine Questionnaire for Students

Frequently Asked Questions
CHAPTER 332

AN ACT concerning immunizations for meningococcal disease and amending P.L.2003, c.284.

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

1. Section 2 of P.L.2003, c.284 (C.18A:62-15.1) is amended to read as follows:


2. a. Beginning in September 2004, a new student enrolling in a public or private institution of higher education in this State shall have received immunization for meningococcal disease as recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention as a condition of attendance at that institution, except as provided in section 3 of P.L.2003, c.284 (C.18A:62-15.2).

b. A student shall present evidence of the vaccination required pursuant to subsection a. of this section to the institution in a manner prescribed by the institution.

c. The Department of Health shall require each public or private institution of higher education in this State to offer the immunization required pursuant to subsection a. of this section to its students through the institution's student health services program or through a contractual agreement with a community health care provider.


2. The Commissioner of Health shall adopt rules and regulations pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.) to carry out the purposes of this act.

3. This act shall take effect on June 15 next following the date of enactment, except that the Commissioner of Health may take administrative action in advance as necessary to effectuate this act.

For persons at increased risk for MenACWY, see increased risk table and the corresponding vaccination schedule below.

**Increased Risk (health condition or other risk factor)**

- **First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older)**
  - Vaccination Schedule: 1 dose MenACWY

- **Functional or anatomic asplenia (including sickle cell disease), HIV infection, persistent complement deficiency or use of complement inhibitor (e.g., eculizumab)**
  - Vaccination Schedule: Administer 2-dose MenACWY at least 8 weeks apart and revaccinate every 5 years if risk remains

- **Travel in countries with hyperendemic or epidemic meningococcal disease, microbiologists routinely exposed to Neisseria meningitidis**
  - Vaccination Schedule: 1 dose MenACWY and revaccinate every 5 years if risk remains

- **Persons at risk during an outbreak declared by public health authorities**
  - Vaccination Schedule: Follow advice of public health authorities

**Recommendation for routine administration of MenACWY:**
- Dose #1 at 11-12 years of age
- Dose #2 at 16 years of age

Vaccine recommendations may differ for those who are considered at increased risk. Please review the table at the bottom of the page to see which health conditions or other risk factors may place a person at increased risk.
**Algorithm for MenB Immunization of College Students 16 Years of Age and Older**

See the Centers for Disease Control and Prevention (CDC) website for complete immunization schedules at: [www.cdc.gov/vaccines/schedules/](http://www.cdc.gov/vaccines/schedules/).

**Recommendation for routine administration of MenB:**
Adolescents and young adults (16 through 23 years old) may choose to receive vaccination based on shared clinical decision-making. The preferred age for receipt is 16 through 18 years.

*Vaccine recommendations may differ for those who are considered at increased risk. Please review the table at the bottom of the page to see which health conditions or other risk factors may place a person at increased risk.*

---

**Primary Series Recommendations**

<table>
<thead>
<tr>
<th>Type of Vaccine</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bexsero</td>
<td>2 doses [4 weeks apart]</td>
</tr>
<tr>
<td>Trumenba—2 Dose</td>
<td>2 doses [at 0 and 6 months]</td>
</tr>
<tr>
<td>Trumenba—3 Dose</td>
<td>3 doses [at 0, 1-2, and 6 months]</td>
</tr>
</tbody>
</table>

**NOTE:** Bexsero and Trumenba are NOT interchangeable. For vaccination series completion, the same MenB vaccine product previously administered must be used to complete the series.

---

**For those who choose to be vaccinated,** begin or complete the primary series of MenB vaccine. If the vaccine series is already completed, no additional doses are recommended for persons not at increased risk.

**NOTE:** The 2-dose schedule of Bexsero or Trumenba may be used for persons not at increased risk. If dose #2 of the 2-dose Trumenba schedule is administered earlier than 6 months after dose #1, a 3rd dose should be administered at least 4 months after dose #2.

---

**Is person at increased risk?**

**NO**

For those who choose to be vaccinated, begin or complete the primary series of MenB vaccine. If the vaccine series is already completed, no additional doses are recommended for persons not at increased risk.

**YES**

For persons at increased risk for MenB, see increased risk table and the corresponding vaccination schedule below.

---

**Increased Risk (health condition or other risk factor)**

- Functional or anatomic asplenia (including sickle cell disease)
- Persistent complement deficiency or use of complement inhibitor (e.g., eculizumab)
- Microbiologists routinely exposed to *Neisseria meningitidis*

**Vaccination Schedule**

Administer primary series and boosters* of either:

- 2-dose schedule of Bexsero
- 3-dose schedule of Trumenba

**Persons at risk during an outbreak declared by public health authorities**

Follow advice of public health authorities

---

*The first booster dose should be given 1 year after the primary series and repeated every 2–3 years as long as the increased risk remains. Booster doses are not recommended for healthy adolescents routinely vaccinated with MenB vaccine.*
Meningococcal ACWY Vaccine for College Students
Recommendations by Age and Risk Factor

There are 2 types of meningococcal conjugate vaccines available in the United States Menactra® and Menveo®. A separate vaccine is needed for protection against meningococcal serogroup B disease.

| Routine Recommendations for Use of Meningococcal A, C, W, Y Vaccine (MenACWY) |
|----------------------------------|-----------------------------------------------|
| **WHOM TO VACCINATE**            | **VACCINATION SCHEDULE**                      |
| Ages 11 through 12 years         | Give dose #1 of 2-dose series. (Dose #2 is recommended at 16 years.) |
| Ages 13 through 15 years         | Give catch-up dose #1 of 2-dose series. (Dose #2 will be due at 16 years.¹) |
| Age 16 years                     | Give dose #2.¹ (Separate from dose #1 by at least 8 weeks.) |
| Ages 17 through 18 years (Catch-up) | If dose #2 not given at age 16 years, give dose #2 as catch-up. |
| Ages 16 through 18 years (Catch-up) | If no history of prior vaccination, give 1 dose. |
| First-year college students living in residence halls | If no history of prior vaccination, give 1 dose. If history of 1 dose given when younger than 16 years of age, give dose #2. |

<table>
<thead>
<tr>
<th>Risk-based Recommendations for Persons with Underlying Medical Conditions or Other Risk Factors [Ages 16 years and older]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TARGETED GROUP BY AGE/OR RISK FACTOR</strong></td>
</tr>
<tr>
<td>Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic, and other people with prolonged increased risk for exposures (e.g., microbiologists routinely working with <em>Neisseria meningitidis</em>)</td>
</tr>
<tr>
<td>People with persistent complement component deficiencies or use of a complement inhibitor (e.g., eculizumab)</td>
</tr>
<tr>
<td>People with HIV infection or functional or anatomic asplenia (including sickle cell disease)</td>
</tr>
<tr>
<td>Persons who are at risk during an outbreak</td>
</tr>
</tbody>
</table>

Contraindications: Do not administer meningococcal vaccines to a person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose or a person who has a severe allergy to any vaccine component.

Precautions: Moderate or severe acute illnesses with or without fever. See [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html).

¹ The minimum interval between doses of MenACWY is 8 weeks.
Meningococcal B Vaccine for College Students
Recommendations by Age and Risk Factor

### Meningococcal Serogroup B Vaccines

<table>
<thead>
<tr>
<th>Vaccine Types</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Bexsero (MenB-4C, GlaxoSmithKline)</td>
<td>The two brands of MenB vaccines are <strong>not</strong> interchangeable. The series must be started and completed with the same brand of vaccine.</td>
</tr>
<tr>
<td>• Trumenba (MenB-FHbp, Pfizer)</td>
<td></td>
</tr>
</tbody>
</table>

### Recommendations Meningococcal Serogroup B Vaccination for People Who are Not in a Risk Group (Shared Clinical Decision-Making)

<table>
<thead>
<tr>
<th>WHOM TO VACCINATE</th>
<th>VACCINATION SCHEDULE</th>
</tr>
</thead>
</table>
| Teens and young adults ages 16 through 23 who wish to be vaccinated. The preferred age for vaccination is 16 through 18 years. | Based on shared clinical decision-making between the healthcare provider and the patient, administer either:  
• **Bexsero**: Give 2 doses, 4 weeks apart, or  
• **Trumenba**: Give 2 doses 6 months apart. If dose #2 is administered earlier than 6 months after dose #1, give a third dose at least 4 months after dose #2. |

### Risk-based Recommendations for Persons with Underlying Medical Conditions or Other Risk Factors

<table>
<thead>
<tr>
<th>WHOM TO VACCINATE</th>
<th>PRIMARY DOSES</th>
<th>BOOSTER DOSE(S)</th>
</tr>
</thead>
</table>
| For people ages 10 years or older with:  
• Persistent complement component deficiencies or use of a complement inhibitor (e.g., eculizumab)  
• Anatomic or functional asplenia, including sickle cell disease | Administer either:  
• **Bexsero**: Give 2 doses, 4 weeks apart, or  
• **Trumenba**: Give 3 doses on a 0-, 1-2, and 6-month schedule. | The first booster dose should be given 1 year after the primary series and repeated every 2–3 years as long as the increased risk remains. |
| For people ages 10 years or older who:  
• Are present during outbreaks caused by serogroup B 1  
• Have prolonged increased risk for exposure (e.g. microbiologists routinely working with Neisseria meningitidis) |

**NOTE:** On June 27, 2019, the Advisory Committee on Immunization Practices (ACIP) voted to recommend booster doses of MenB vaccine for people at increased risk of meningococcal disease. Booster doses are not recommended for healthy adolescents routinely vaccinated with MenB vaccine.

### Contraindications
Do not administer meningococcal vaccines to a person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose or a person who has a severe allergy to any vaccine component.

### Precautions
Moderate or severe illness with or without fever. Pregnancy. See [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html).
Meningococcal Disease for College Students

New Jersey law requires that certain students receive meningococcal vaccines!

Are you protected?

What is meningococcal disease?
Meningococcal (muh-nin-jo-cok-ul) disease is a serious bacterial infection caused by *Neisseria meningitidis*. The bacteria can invade the body, leading to severe swelling of the tissue surrounding the brain and spinal cord (meningitis) or bloodstream infection. Both of these types of infections are very serious and can be deadly in a matter of hours. Even with antibiotic treatment, 10 to 15 in 100 people infected with meningococcal disease will die. Up to 1 in 5 survivors will have long-term disabilities, such as loss of limb(s), deafness, nervous system problems, or brain damage.

How do people get meningococcal disease?
People spread meningococcal bacteria by sharing respiratory and throat secretions (saliva/spit). Generally, the bacteria are spread by close or lengthy contact with a person who has meningococcal disease such as:
- People in the same household
- Roommates
- Anyone with direct contact with the patient’s oral secretions such as through kissing or sharing eating utensils, cigarettes/vaping devices, and food.

What are the symptoms of meningococcal disease?
Symptoms can progress quickly and may include:
- high fever
- headache
- stiff neck
- confusion
- sensitivity to light
- nausea
- vomiting
- exhaustion
- purplish rash

Some people carry the bacteria in their noses and throat, but they don’t become ill. Even though they do not have symptoms, they can still spread the bacteria to others.

How can I protect myself from meningococcal disease?
The best way to protect yourself from meningococcal disease is to get vaccinated. There are two types of meningococcal vaccines that protect against the common serogroups (A, B, C, W, Y) of the bacteria:
- Meningococcal conjugate or MenACWY vaccines (Menveo® or Menactra®)
- Serogroup B meningococcal or MenB vaccines (Bexsero® or Trumenba®)

For more information, please visit [https://nj.gov/health/cd/topics/meningo.shtml](https://nj.gov/health/cd/topics/meningo.shtml), or contact the NJDOH Vaccine Preventable Disease Program at 609-826-4861.
Do I need meningococcal vaccines to attend a college in New Jersey?

If you are a new student enrolling in a public or private institution of higher education in New Jersey, you are required by state law (P.L. 2019, c.332 [N.J.S.A.18A:62-15.1]) to receive meningococcal vaccines as recommended by the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC). The CDC recommends:

**MenACWY (Menactra® and Menevo®)** vaccine is routinely recommended at ages 11-12 years with a booster dose at 16 years. Adolescents who receive their first dose of MenACWY vaccine on or after their 16th birthday do not need a booster dose. Additional doses may be recommended based on risk. People 19 years of age and older are not routinely recommended to receive the MenACWY vaccine unless they are first-year college students living in residential housing or if another risk factor applies.

**MenB (Bexsero® and Trumenba®)** vaccine is routinely recommended for people ages 10 years or older with high-risk health conditions. People 16-23 years old (preferably at ages 16-18 years) may also choose to get a MenB vaccine.

Below is a summary of requirements based on student age and risk.

### By age indication

<table>
<thead>
<tr>
<th>Age</th>
<th>MenACWY Requirement</th>
<th>MenB Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤18 years of age, not at increased risk</td>
<td>Vaccine required</td>
<td>Vaccine not required*</td>
</tr>
<tr>
<td>≥19 years of age, not at increased risk</td>
<td>Vaccine not required</td>
<td>Vaccine not required*</td>
</tr>
</tbody>
</table>

### By increased risk indication†

<table>
<thead>
<tr>
<th>Indication</th>
<th>MenACWY Requirement</th>
<th>MenB Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-year college student living in residence hall or military recruit</td>
<td>Vaccine required</td>
<td>Vaccine not required</td>
</tr>
<tr>
<td>Complement component deficiency or use of a medication known as a complement inhibitor (e.g., eculizumab)</td>
<td>Vaccine required</td>
<td>Vaccine required</td>
</tr>
<tr>
<td>No spleen or problem with spleen — including sickle cell disease</td>
<td>Vaccine required</td>
<td>Vaccine required</td>
</tr>
<tr>
<td>HIV infection</td>
<td>Vaccine required</td>
<td>Vaccine not required</td>
</tr>
<tr>
<td>Travel to an area where the disease is common. Check <a href="http://www.cdc.gov/travel">www.cdc.gov/travel</a> for travel-related risk.</td>
<td>Vaccine required</td>
<td>Vaccine not required</td>
</tr>
<tr>
<td>Work in a laboratory with meningococcal bacteria (Neisseria meningitidis)</td>
<td>Vaccine required</td>
<td>Vaccine required</td>
</tr>
<tr>
<td>Part of an outbreak as declared by public health officials — you will be notified if this applies</td>
<td>Vaccine required if outbreak caused by serogroup A, C, W or Y</td>
<td>Vaccine required if outbreak caused by serogroup B</td>
</tr>
</tbody>
</table>

*Though MenB vaccination is not required, persons 16-23 years old may choose to receive MenB vaccine to provide short-term protection against most strains of MenB disease. Learn more about meningococcal disease and MenB vaccination at: [www.cdc.gov/meningococcal](http://www.cdc.gov/meningococcal).

†Check with your healthcare provider to determine the best vaccine series and booster schedule for you.

Are these vaccines safe?

Meningococcal vaccines are safe and effective. As with all vaccines, there can be minor reactions, including pain and redness at the injection site or a mild fever. Severe side effects, such as a serious allergic reaction, are very rare.

Where can I get these vaccines?

In accordance with *P.L. 2019, c.332*, each institution must offer required meningococcal vaccines through the student health service or through a contracted agreement with a community health provider. Most insurance plans cover recommended vaccines. If you are under 19 years of age, ask your healthcare provider if they participate in the New Jersey Vaccines for Children (VFC) Program. You may qualify for free or low-cost vaccines. You can also check with college health services, local health departments, and federally qualified health centers regarding vaccine affordability.
New Jersey law requires that new students enrolling in a public or private institution of higher education in New Jersey to have received meningococcal vaccines as recommended by the Advisory Committee on Immunization Practices (ACIP). There are two types of meningococcal vaccines that might be required depending on your age and your risks: the meningococcal conjugate vaccine (MenACWY) that protects against serogroups A, C, W, and Y disease; and the meningococcal serogroup B vaccine (MenB) that protects against serogroup B disease.

By age indication

<table>
<thead>
<tr>
<th>Age</th>
<th>MenACWY Requirement</th>
<th>MenB Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤18 years of age, not at increased risk</td>
<td>✓ Vaccine required</td>
<td>× Vaccine not required*</td>
</tr>
<tr>
<td>≥19 years of age, not at increased risk</td>
<td>× Vaccine not required</td>
<td>× Vaccine not required*</td>
</tr>
</tbody>
</table>

By increased risk indication

<table>
<thead>
<tr>
<th>Indication</th>
<th>MenACWY Requirement</th>
<th>MenB Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-year college student living in residence hall or military recruit</td>
<td>✓ Vaccine required</td>
<td>× Vaccine not required*</td>
</tr>
<tr>
<td>Complement component deficiency or use of a medication known as a complement inhibitor (e.g., eculizumab)</td>
<td>✓ Vaccine required</td>
<td>✓ Vaccine required</td>
</tr>
<tr>
<td>No spleen or problem with spleen – including sickle cell disease</td>
<td>✓ Vaccine required</td>
<td>✓ Vaccine required</td>
</tr>
<tr>
<td>HIV infection</td>
<td>✓ Vaccine required</td>
<td>× Vaccine not required*</td>
</tr>
<tr>
<td>Travel to an area where the disease is common. Check <a href="http://www.cdc.gov/travel">www.cdc.gov/travel</a> for travel-related risk</td>
<td>✓ Vaccine required</td>
<td>× Vaccine not required*</td>
</tr>
<tr>
<td>Work in a laboratory with meningococcal bacteria (Neisseria meningitidis)</td>
<td>✓ Vaccine required</td>
<td>✓ Vaccine required</td>
</tr>
<tr>
<td>Part of an outbreak as declared by public health officials—you will be notified if this applies to you</td>
<td>Vaccine required if outbreak caused by serogroup A, C, W or Y</td>
<td>Vaccine required if outbreak caused by serogroup B</td>
</tr>
</tbody>
</table>

*Though MenB vaccination is not required, persons 16-23 years old may choose to receive MenB vaccine to provide short-term protection against most strains of MenB disease. Learn more about meningococcal disease and MenB vaccination at: [www.cdc.gov/meningococcal](http://www.cdc.gov/meningococcal).

INSTRUCTIONS: To assist in determining which meningococcal vaccines may be required for you, review each of the indications in the table below, both by age and by increased risk. Place a checkmark in the box next to each indication that applies to you.

Please consult with your healthcare provider if you have questions about the meningococcal vaccines or if you need to receive the vaccines to attend a New Jersey institution of higher education.
Meningococcal Vaccination Requirement for Higher Education

Frequently Asked Questions

New Jersey law requires that new students enrolling in a public or private institution of higher education in New Jersey have received meningococcal vaccines as recommended by the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Prevention and Control (CDC). The following frequently asked questions have been listed below for your guidance.

FAQs

STUDENT FAQs

I am entering college next semester. Will I need the meningococcal vaccines? ................................................... 2

Which meningococcal vaccines do I need? ........................................................................................................ 2

I received a dose of MenACWY vaccine at 11 years old to attend sixth grade in New Jersey. Why do I still need another dose of MenACWY for college? ................................................................. 2

I am a first-year college student living in a campus residence hall, do I need meningococcal vaccines?..............2

Can titers be accepted in lieu of documentation of vaccination? ............................................................................... 3

Do I have to get a meningococcal vaccine if I have a medical condition that prevents me from receiving it?.....3

Do I have to get a meningococcal vaccine if I practice a religion that prevents me from receiving it? ...............3

Where can I obtain my vaccination records? ........................................................................................................ 3

What is the New Jersey Immunization Information System (NJIIS)? ................................................................. 3

If I can’t find my vaccination records, do I need to get the vaccination again? .................................................... 3

COLLEGE HEALTH ADMINISTRATOR FAQS

Will vaccination be required during an outbreak? ................................................................................................. 3

How do I know which students are considered at increased risk? ........................................................... 4

The ACIP states the MenACWY is recommended for first-year college students who live in residential housing if not previously vaccinated at age 16 years of age and older. How is a first-year student defined?........4

Is there a medical exemption form? .................................................................................................................. 4

Are students 31 years of age and older subject to the immunization requirements set forth in N.J.A.C. 8:57-6.4 (b)1 since the Higher Education statute N.J.S.A. 18A:61D-1 states that the immunization requirements specifically apply to students 30 years of age and under? ................................................................. 4

Is the previous law requiring education on meningococcal disease still in effect? ......................................... 5

CLINICIAN FAQS

How do shared clinical decision-making recommendations differ from routine, catch-up, and risk-based immunization recommendations? ............................................................................................... 5

Which patients should providers discuss shared clinical decision-making recommendations with? ..........5

Are shared clinical decision-making recommendations covered by private insurers? ........................................ 5

Are the two MenACWY vaccines interchangeable? ............................................................................................. 6
Are the two MenB vaccines interchangeable? ...................................................................................................... 6
Can both MenACWY and MenB vaccines be administered on the same day? .................................................... 6
If a patient received MenACWY vaccine at age 10 years and a dose of MenACWY before the 16th birthday, will they still need a booster dose at age 16? ........................................................................................................ 6

Risk Indication Summary Table............................................................................................................................ 6

STUDENT FAQs

I am entering college next semester. Will I need the meningococcal vaccines?

  YES, new students enrolling in a public or private institution of higher education in New Jersey are required by state law (P.L. 2019, c.332) to receive meningococcal vaccines as recommended by the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC).

Which meningococcal vaccines do I need?

  There are two types of meningococcal vaccines that might be required depending on your age and your risk. The meningococcal conjugate vaccine (MenACWY) protects against serogroups A, C, W and Y disease. The meningococcal serogroup B vaccine (MenB) protects against serogroup B disease. You are required to receive meningococcal vaccines that are routinely recommended for you. Please review the student questionnaire and/or speak with your healthcare provider to determine which vaccines you may need.

I received a dose of MenACWY vaccine at 11 years old to attend sixth grade in New Jersey. Why do I still need another dose of MenACWY for college?

  CDC recommends a dose of MenACWY vaccine at ages 11-12 years with a booster dose at 16 years. This is because protection from the first dose begins to wane, so a booster dose is recommended to provide greater protection from meningococcal disease. College students, especially freshman living in residence halls, are at a slightly increased risk for contracting meningococcal disease. All students 16 through 18 will be required to receive a dose of MenACWY (Menactra or Menveo) on or after age 16 even if you received a dose at a younger age. Additionally, all first-year college students who are living in residence halls will be required to have received a dose of MenACWY on or after the 16th birthday.

I am a first-year college student living in a campus residence hall, do I need meningococcal vaccines?

  YES, you will be required to receive MenACWY if you are a first-year college student living in a residence hall regardless of age. If you received at least one dose of MenACWY on or after age 16, no further doses are necessary unless you have a risk factor for meningococcal disease.

You will be required to receive MenB vaccine (Bexsero or Trumenba) for school attendance if you have a risk factor. Anyone 16 through 23 years old (preferably at 16 – 18 years of age) may choose to receive MenB vaccine. MenB vaccines provide short-term protection against most strains of serogroup B meningococcal disease.

A summary table of increased risk indications is included at the end of the FAQs.
Can titers be accepted in lieu of documentation of vaccination?
➢ NO, there are no acceptable serologic titers that can be used as evidence of protection against meningococcal strains A, B, C, W, or Y.

Do I have to get a meningococcal vaccine if I have a medical condition that prevents me from receiving it?
➢ NO, the ACIP provides guidance to healthcare providers on which patients should not receive a particular vaccine. These reasons are listed at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. For all medical exemptions, your physician must provide information to your school that satisfies the following:
   • Only a physician licensed to practice medicine/osteopathic medicine and a nurse practitioner can write a medical exemption.
   • A medical exemption must indicate a specific period of time in which the student cannot receive specific vaccinations.
   • Reason(s) for medical contraindication must be enumerated by the ACIP and the American Academy of Pediatrics (AAP).
   A medical exemption form is also available on the NJDOH website at www.nj.gov/health/forms/imm-53.pdf.

Do I have to get a meningococcal vaccine if I practice a religion that prevents me from receiving it?
➢ NO, according to N.J.S.A.18A:61D-3, a student can submit a written statement that the immunization conflicts with the student’s religious beliefs. Philosophical, moral or conscientious exemptions are not acceptable.

Where can I obtain my vaccination records?
➢ If you do not currently have a copy of your vaccine records, you may be able to retrieve an official copy by contacting your: healthcare provider, the state immunization registry (New Jersey Immunization Information System – njiis.nj.gov – see question below for more info), or a previous school.

What is the New Jersey Immunization Information System (NJIIS)?
➢ NJIIS is the statewide immunization registry. NJIIS consolidates immunization information from all healthcare providers into one official record. More information on the registry can be found at https://nj.gov/health/cd/documents/vpdp/njiis_information_adults.pdf.

If I can’t find my vaccination records, do I need to get the vaccination again?
➢ YES, documentation of vaccination including the date of administration is required for attendance at institutions of higher education. If no record is available, then revaccination would be required.

COLLEGE HEALTH ADMINISTRATOR FAQs

Will vaccination be required during an outbreak?
➢ YES, vaccination will be required for outbreaks of meningococcal disease with serogroups in the meningococcal vaccines (A, B, C, W, Y). The outbreak must be declared by public health authorities. The specifics of the vaccine required, and the vaccination schedule will be determined by public health authorities.
How do I know which students are considered at increased risk?

- Institutions shall develop policies and procedures to determine a student’s risk-status based on the ACIP recommendations. A summary table of increased risk indications is included at the end of the FAQs.

The ACIP states the MenACWY is recommended for first-year college students who live in residential housing if not previously vaccinated at age 16 years of age and older. How is a first-year student defined?

- This recommendation only applies to first-year/freshman college students who are also living in campus residential housing. Unvaccinated students 19 years of age and older who are not first-year college students (e.g., students transferring from another college as a second-year student, previous commuter students) would not be required to receive the vaccine, even if the student is living in residential housing. Although the MenACWY vaccine is not required, any student newly living in campus residential housing can discuss their individual risk with their healthcare provider. Please note that all adolescents, regardless of whether they will be attending college or living on campus, should receive 2 doses of MenACWY vaccine at 11-12 and 16-18 years. Therefore, any college student under 19 years of age would be required to be vaccinated.

Is there a medical exemption form?

- YES, the New Jersey Department of Health (NJDOH) created a Request for Medical Exemption from Mandatory Immunization Form (IMM-53) and guidance document available at www.nj.gov/health/forms/imm-53.pdf. Healthcare providers who submit medical exemptions for mandatory vaccination must ensure that the information submitted is accurate and verifiable. The use of this form is not mandated or required. It is a tool that may be used by healthcare providers, schools, preschools, childcare facilities, and local health departments to assist in determining the validity of a medical exemption from mandatory immunization.

Are students 31 years of age and older subject to the immunization requirements set forth in N.J.A.C. 8:57-6.4 (b)1 since the Higher Education statute N.J.S.A. 18A:61D-1 states that the immunization requirements specifically apply to students 30 years of age and under?

- The NJ Higher Education Statute, N.J.S.A. 18A:61D-1 states: Every public and independent institution of higher education in this State shall, as a condition of admission or continued enrollment, require every graduate and undergraduate student who is 30 years of age or less and is enrolled full-time or part-time in a program or course of study leading to an academic degree, to submit to the institution a valid immunization record which documents the administration of all required immunizations against vaccine-preventable disease, or evidence of immunity from these diseases, in accordance with regulations promulgated by the Department of Health. The institution shall keep the records on file in such form and manner as prescribed by the department.

The NJDOH administrative code, N.J.A.C. 8:57-6.4, states that students born before 1957 are exempt from the measles, mumps, and rubella (MMR) vaccination requirement. Since the Education Statute at N.J.S.A. 18A:61D-1 specifically states that only students 30 years of age or less must show proof of vaccination, NJDOH cannot require a college student over 30 years of age that meets all the other requirements set forth at N.J.S.A. 18A:61D-1 to present proof of vaccine or immunity for any of the required college vaccines. However, NJDOH still highly recommends that students are age-appropriately immunized.
Is the previous law requiring education on meningococcal disease still in effect?

- **YES**, it is still required for institutions to provide education on meningococcal disease. Since 2001, institutions of higher education have been required by law (N.J.A.C. 8:57-6.10) to provide information on meningococcal disease, at a minimum, including its nature and severity, causes, disease prevention and treatments, and the availability of a meningococcal vaccine to prevent disease. The student information flyer, available at [https://nj.gov/health/cd/topics/meningo.shtml](https://nj.gov/health/cd/topics/meningo.shtml), may be shared to comply with this law. Alternatively, an institution may develop their own resource to comply.

**CLINICIAN FAQs**

How do shared clinical decision-making recommendations differ from routine, catch-up, and risk-based immunization recommendations?

- Unlike routine, catch-up, and risk-based recommendations, shared clinical decision-making vaccinations are not recommended for everyone in a particular age group or everyone in an identifiable risk group. Rather, shared clinical decision-making recommendations are individually based and informed by a decision process between the health care provider and the patient or parent/guardian.

The key distinction between routine, catch-up, and risk-based recommendations and shared clinical decision-making recommendations is the default decision to vaccinate. For routine, catch-up, and risk-based recommendations, the default decision should be to vaccinate the patient based on age group or other indication, unless contraindicated. For shared clinical decision-making recommendations, there is no default—the decision about whether or not to vaccinate may be informed by the best available evidence of who may benefit from vaccination; the individual’s characteristics, values, and preferences; the health care provider’s clinical discretion; and the characteristics of the vaccine being considered. There is not a prescribed set of considerations or decision points in the decision-making process.

Which patients should providers discuss shared clinical decision-making recommendations with?

- It’s up to the provider. Some health care providers may choose to discuss immunizations recommended for shared clinical decision-making with all or most of their patients who could receive it, while some providers may be more selective when discussing these immunizations with their patients. Health care providers should also be receptive to patient-initiated conversations about these immunizations.

Are shared clinical decision-making recommendations covered by private insurers?

- Under the Affordable Care Act and its implementing regulations, ACIP recommendations that have been adopted by CDC “with respect to the individual involved” and are “listed on the Immunization Schedules of the Centers for Disease Control and Prevention” generally are required to be covered by group health plans and health insurance issuers offering group or individual health insurance coverage without imposing any cost-sharing requirements (such as a copayment, coinsurance, or deductible). This coverage requirement includes shared clinical decision-making recommendations when they have been adopted by CDC and are listed on the immunization schedules.
Are the two MenACWY vaccines interchangeable?

- **YES**, for persons age 9 months and older the vaccines, MenACWY-D (Menactra) and MenACWY-CRM (Menveo), are interchangeable.

Are the two MenB vaccines interchangeable?

- **NO**, the two MenB vaccines, MenB-4C (Bexsero) and MenB-FHbp (Trumenba), are not interchangeable. If a series is started with one brand, it must be completed with the same brand.

Can both MenACWY and MenB vaccines be administered on the same day?

- **YES**, these two vaccines can be administered at the same visit or at any time before or after the other. There is no need for spacing between these two vaccines.

If a patient received MenACWY vaccine at age 10 years and a dose of MenACWY before the 16th birthday, will they still need a booster dose at age 16?

- **YES**, they should receive a booster dose. A booster dose of MenACWY is recommended at age 16 years even if 2 (or more) doses of meningococcal ACWY vaccine were received before age 16 years.

### Risk Indication Summary Table

<table>
<thead>
<tr>
<th>Risk Indications</th>
<th>Meningococcal ACWY (MenACWY)</th>
<th>Meningococcal B (MenB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complement component deficiency</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Anatomic/functional asplenia</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>HIV infected</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Travel</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Microbiologist working with <em>N. Meningitidis</em></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>First-year college student living in residence hall</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Military recruit</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Community outbreak</td>
<td>Yes, for outbreaks involving serogroups A, C, W, Y</td>
<td>Yes, for outbreaks involving serogroup B</td>
</tr>
</tbody>
</table>

**Last updated:** February 25, 2020